

NOTIFICATION PURSUANT TO

18 V.S.A. § 4637(b)

Subject: Notification Pursuant to 18 V.S.A. § 4637(b)

To the Office of the Attorney General of Vermont:

Genentech USA, Inc. hereby notifies the Attorney General of Vermont of the following new prescription drug, pursuant to 18 V.S.A. § 4637(b):

Name of New Prescription Drug	NDC Number	Date of Commercial Availability	WAC (Wholesale Acquisition Cost) (As of the Date of Commercial Availability)
Columvi 2.5mg/2.5mL Vial	50242-0125-01	June 27, 2023	\$ 2,554.74
Columvi 10mg/10mL Vial	50242-0127-01	June 27, 2023	\$ 10,218.98

Randall Woo State Government Programs Manager Genentech USA, Inc.

į.